Exozymes (EXOZ) Total Liabilities (2023 - 2026)
Exozymes (EXOZ) posted quarterly Total Liabilities of $2.6 million for Q4 2025, down 1.51% year-over-year from $2.6 million in Q4 2024, and up 9.79% quarter-over-quarter from $2.3 million in Q3 2025.
Exozymes (EXOZ) Total Liabilities (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Total Liabilities for 3 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 1.51% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (down 1.51% YoY), while the FY2025 annual figure was $2.6 million, down 1.51% from the prior year.
- Total Liabilities grew to $2.6 million in Q4 2025 per EXOZ's latest filing, from $2.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $7.2 million in Q3 2024 and bottomed at $2.3 million in Q3 2025.
- Historically, Total Liabilities has averaged $3.4 million across 3 years, with a median of $2.6 million in 2024.
- On a YoY basis, Total Liabilities climbed as much as 1.51% in 2025 and fell as far as 67.26% in 2025.
- Exozymes' Total Liabilities stood at $3.9 million in 2023, then slumped by 33.71% to $2.6 million in 2024, then declined by 1.51% to $2.6 million in 2025.
- Business Quant data shows EXOZ's Total Liabilities at $2.6 million in Q4 2025, $2.3 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Exozymes | 64.09 Mn | 64.09 Mn | - | 4.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 7.16 Mn |
| Dec 31, 2023 | 3.94 Mn |